A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge

• Váldodahkkit: Ruixiao Du (Dahkki), Qunying Mao (Dahkki), Yalin Hu (Dahkki), Shuhui Lang (Dahkki), Shiyang Sun (Dahkki), Kelei Li (Dahkki), Fan Gao (Dahkki), Lianlian Bian (Dahkki), Ce Yang (Dahkki), Bopei Cui (Dahkki), Longfa Xu (Dahkki), Tong Cheng (Dahkki), Zhenglun Liang (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2019-10-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Coxsackievirus A16 (CA16) has caused worldwide epidemics of hand, foot and mouth disease (HFMD), particularly in infants and pre-school children. Currently, there are no vaccines or antiviral drugs available for CA16-associated disease. In this study, a CA16-specific monoclonal antibody (MAb) NA11F1...